These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 17595837)

  • 1. Pharmaceuticals--strategic considerations in health reforms in Pakistan.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S100-11. PubMed ID: 17595837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Gateway Paper--context and configuration of the proposed health reforms in Pakistan.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S2-13. PubMed ID: 17595829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Gateway Paper--health service delivery outside of the public sector in Pakistan.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S66-77. PubMed ID: 17595834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Gateway Paper--proposed health reforms in Pakistan--interface considerations.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S78-93. PubMed ID: 17595835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence from research and its implications for health reforms in Pakistan: the Gateway Paper perspective.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S112-9. PubMed ID: 17595838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Gateway Paper--public sector service delivery infrastructure and health reforms in Pakistan.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S43-50. PubMed ID: 17595832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Gateway Paper--stewardship and governance in the health sector in Pakistan.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S14-24. PubMed ID: 17595830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Gateway Paper--preventive and promotive programs in Pakistan and health reforms in Pakistan.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S51-65. PubMed ID: 17595833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Gateway Paper--financing health in Pakistan and its linkage with health reforms.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S25-42. PubMed ID: 17595831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human resource solutions--the Gateway Paper proposed health reforms in Pakistan.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S94-9. PubMed ID: 17595836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health reforms in Pakistan--configuring health beyond the health sector.
    Nishtar S
    J Pak Med Assoc; 2006 Dec; 56(12 Suppl 4):S120-35. PubMed ID: 17595839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug supply strategies, constraints and prospects in Nigeria.
    Yusuff KB; Tayo F
    Afr J Med Med Sci; 2004 Dec; 33(4):389-94. PubMed ID: 15977451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of national drug policies--regional comparison between Bulgaria, Romania, Macedonia, Bosnia Herzegovina.
    Petrova GI
    Cent Eur J Public Health; 2001 Nov; 9(4):205-13. PubMed ID: 11787250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Mechanism and implication of regulation of the pricing of essential medicines in the private pharmaceutical sector in Mali].
    Maïga D; Maïga S; Maïga MD
    Med Trop (Mars); 2010 Apr; 70(2):184-8. PubMed ID: 20486360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to essential drugs in Guyana: a public health challenge.
    Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Health Plann Manage; 2010; 25(1):2-16. PubMed ID: 18536003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Centralized purchasing of essential drugs, a priority for the health care systems of developing countries].
    Blaise P; Dujardin B; de Béthune X; Vandenbergh D
    Sante; 1998; 8(3):217-26. PubMed ID: 9690323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical policy of the Andean sub-region.
    Essent Drugs Monit; 1993; (16):13-5. PubMed ID: 12319050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intervention studies on rational use of drugs in public and private sector in Nepal.
    Kafle KK; Shrestha N; Karkee SB; Prasad RR; Bhuju GB; Das PL
    Nepal Med Coll J; 2005 Jun; 7(1):47-50. PubMed ID: 16295722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.